Literature DB >> 15976067

A new, accurate and conventional five-point method for quantitative evaluation of ascites using plain computed tomography in cancer patients.

Noboru Oriuchi1, Takahito Nakajima, Erito Mochiki, Izumi Takeyoshi, Tatsuya Kanuma, Keigo Endo, Junichi Sakamoto.   

Abstract

BACKGROUND: To assess the exact response of the malignant ascites to the treatment, the objective measurement of the volume of ascites is essential. We have developed a simple method to measure the volume of ascites by using standard abdomino-pelvic computed tomography (CT). The aim of the study is to validate the accuracy of the measurements by comparing them with the standard volume calculation by using 3D-CT.
METHODS: Twelve consecutive patients with cancer who had measurable ascites underwent 15 helical CT examinations. On conventional CT images, the thickness of ascites in centimeters was measured in three planes such as the bilateral subphrenic space (A and B), the bilateral paracolic space (C and D) and the pre-bladder space (E), and the average thickness: (A + B + C + D + E)/5 was then multiplied by the area of standard abdominal cavity in the anterior projection, that was assumed to be 1000 cm(2), to yield the volume of ascites: (A + B + C + D + E) x 200 (ml). The volume of ascites was compared with the exact volume, that was obtained from 3D-CT with the volume rendering method.
RESULTS: The volume of ascites measured by the present method and the volume rendering method ranged from 140 to 4040 ml and from 86 to 4279 ml, respectively. The correlation was statistically significant with a correlation coefficient of 0.956 (P < 0.01) using the Spearman's rank correlation. In 13 examinations with the exact volume > or =300 ml, the average ratio of the absolute difference in the volume was 12.9 +/- 13.9% as compared with 62.8 and 162.0% in two examinations with the exact volume < 300 ml.
CONCLUSION: The preliminary study indicated that the present five-point method using a conventional CT was accurate in patients with the volume of ascites > or =300 ml. Because this procedure is simple and easy to perform, it should be feasible in many hospitals for the follow-up of ascites after treatment.

Entities:  

Mesh:

Year:  2005        PMID: 15976067     DOI: 10.1093/jjco/hyi109

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  18 in total

Review 1.  Paclitaxel chemotherapy for the treatment of gastric cancer.

Authors:  Junichi Sakamoto; Takanori Matsui; Yasuhiro Kodera
Journal:  Gastric Cancer       Date:  2009-06-27       Impact factor: 7.370

2.  Validity of the Japanese version of functional assessment of cancer therapy-gastric (FACT-Ga) and its sensitivity to ascites volume change: a retrospective analysis of Japanese clinical trial participants.

Authors:  Hiromichi Maeda; Maho Sato; Michiya Kobayashi; Nobuhiro Takiguchi; Takaki Yoshikawa; Shigefumi Yoshino; Kazuhiro Yoshida; Akira Tsuburaya; Junichi Sakamoto; Satoshi Morita
Journal:  Support Care Cancer       Date:  2016-06-07       Impact factor: 3.603

3.  Predicting the amount of intraperitoneal fluid accumulation by computed tomography and its clinical use in patients with perforated peptic ulcer.

Authors:  Toru Ishiguro; Youichi Kumagai; Hiroyuki Baba; Yusuke Tajima; Hideko Imaizumi; Okihide Suzuki; Koki Kuwabara; Takeaki Matsuzawa; Jun Sobajima; Minoru Fukuchi; Keiichiro Ishibashi; Erito Mochiki; Hideyuki Ishida
Journal:  Int Surg       Date:  2014 Nov-Dec

4.  Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis.

Authors:  Kohei Shitara; Ayako Mizota; Keitaro Matsuo; Yozo Sato; Chihiro Kondo; Daisuke Takahari; Takashi Ura; Masahiro Tajika; Kei Muro
Journal:  Gastric Cancer       Date:  2012-02-24       Impact factor: 7.370

5.  Validation trial for efficacy of ultrasonographic measurement method to predict ascitic volume using virtual ultrasonography.

Authors:  Masashi Hirooka; Yohei Koizumi; Yusuke Imai; Atsushi Yukimoto; Takao Watanabe; Osamu Yoshida; Masanori Abe; Yoichi Hiasa
Journal:  J Med Ultrason (2001)       Date:  2018-04-18       Impact factor: 1.314

Review 6.  Malignant ascites: pathophysiology and treatment.

Authors:  Emanuel Cavazzoni; Walter Bugiantella; Luigina Graziosi; Maria Silvia Franceschini; Annibale Donini
Journal:  Int J Clin Oncol       Date:  2012-03-31       Impact factor: 3.402

7.  Assessing clinical benefit response in the treatment of gastric malignant ascites with non-measurable lesions: a multicenter phase II trial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer.

Authors:  Haruhiko Imamoto; Koji Oba; Junichi Sakamoto; Hiroyasu Iishi; Hiroyuki Narahara; Takeyoshi Yumiba; Takashi Morimoto; Masaki Nakamura; Noboru Oriuchi; Chieko Kakutani; Satoshi Morita; Hitoshi Shiozaki
Journal:  Gastric Cancer       Date:  2011-02-17       Impact factor: 7.370

8.  Phase I/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in advanced gastric cancer patients with peritoneal metastasis.

Authors:  Hyungwoo Cho; Min-Hee Ryu; Kyu-Pyo Kim; Baek-Yeol Ryoo; Sook Ryun Park; Bum Soo Kim; In-Seob Lee; Hee-Sung Kim; Moon-Won Yoo; Jeong Hwan Yook; Seong Tae Oh; Byung Sik Kim; Yoon-Koo Kang
Journal:  Gastric Cancer       Date:  2017-03-16       Impact factor: 7.370

9.  Clinicopathological characteristics and prognosis of gastric cancer with malignant ascites.

Authors:  Nian Fang; Hui-Qing Zhang; Bo He; Mei Xie; Shan Lu; Yi-Ye Wan; Nong-Rong Wang
Journal:  Tumour Biol       Date:  2013-11-27

Review 10.  Evaluation and treatment of malignant ascites secondary to gastric cancer.

Authors:  Hiromichi Maeda; Michiya Kobayashi; Junichi Sakamoto
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.